A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls

Increased leucine‐rich repeat kinase 2 (LRRK2) kinase activity is an established risk factor for Parkinson's disease (PD), and several LRRK2 kinase inhibitors are in clinical development as potential novel disease‐modifying therapeutics. This biomarker characterization study explored within‐ an...

Descripción completa

Detalles Bibliográficos
Autores principales: Vissers, Maurits F. J. M., Troyer, Matthew D., Thijssen, Eva, Pereira, Diana R., Heuberger, | Jules A. A. C., Groeneveld, Geert Jan, Huntwork‐Rodriguez, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432885/
https://www.ncbi.nlm.nih.gov/pubmed/37177855
http://dx.doi.org/10.1111/cts.13541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432885/
https://www.ncbi.nlm.nih.gov/pubmed/37177855
http://dx.doi.org/10.1111/cts.13541

Ejemplares similares